{
 "as_of": "2026-11-06",
 "cmr": "ca-cm-kg/TSXV/RKV",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Rakovina Therapeutics Inc. (TSXV: RKV) — research page\n\nAs of 2026-11-06 · ca-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Rakovina Therapeutics Inc., listed on the TSXV under ticker RKV, with LEI 254900O0YVEUNI9UM016. The ISIN is not on the record. Its security type is Corporate, its segment is not on the record, its sector is Life Sciences, and its jurisdiction is British Columbia (CA-BC). The issuer is listed and not halted.\n\n## The disclosure read\n\nThe record holds 28 filings in the twelve months to 2026-11-06, across 24 filing days. The filings are 21 newswire releases, 4 exchange bulletins and 3 financial statements. The median gap between filing days is 12 days. The latest filing is a newswire release dated 2026-11-05, 1 day before the record date. The TSXV median cadence gap is 19 days, and the TSXV median latency is 17.0 days. The Life Sciences sector median cadence gap is 17.5 days, and the sector median latency is 14 days. The TSXV median filings count is 9, and the sector median filings count is 7.0.\n\n## Auditor\n\nThe auditor of record is Davidson & Company LLP. The auditor's location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting, name change, domicile change or segment move events. The issuer is listed and not halted.\n\n## Orderability\n\nUnder rule version acm-68000/ca/kyp-know-your-product-ni-31-103/r1, chapter as of 2026-11-04, both client categories return signal ACM-200 and the outcome is determinable: Paragraph (o) of the definition and Paragraph (q) of the definition.\n\n## Coverage\n\nNo research houses were found on the issuer's investor-relations pages read. The count is 0.\n\n## Open research\n\nNo openly published research notes were found. The count is 0.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe vintage of this market is not sealed. The live record began on 2026-09-10. Years 2021 through 2026 are sealed in the store but are not served as of a date, and the as-of door answers not_sealed.\n\n## Sources\n\n8 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.tsx.com/json/company-directory/search/tsxv/^* (identity.exchange)\n- https://api.gleif.org/api/v1/lei-records/254900O0YVEUNI9UM016 (identity.jurisdiction)\n- https://www.tsx.com/en/resource/571 (identity.sector)\n- https://mcp.ca-cm-kg.ai/events/TSXV/RKV (the disclosure lines)\n- https://iiroc.mediaroom.com/index.php?s=2429&l=100 (the halt flag)\n- https://www.biospace.com/press-releases/rakovina-therapeutics-announces-q2-2026-financial-results-and-provides-corporate-update (the auditor)\n- https://mcp.ca-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://mcp.ca-cm-kg.ai/record/TSXV/RKV (the record)\n",
 "market": "CA",
 "node": "ca-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": "2026-09-10",
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "6 years are sealed in the CA store; their Replay split is not built, so the as-of door answers not_sealed and the record is the live record as of 2026-11-06",
   "record_version": 1,
   "sealed": false,
   "store_years_sealed_not_served": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ]
  },
  "auditor": {
   "auditor": {
    "read_by": "Tavily regex",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.biospace.com/press-releases/rakovina-therapeutics-announces-q2-2026-financial-results-and-provides-corporate-update",
    "state": "sourced",
    "value": "Davidson & Company LLP"
   },
   "auditor_firm_id": {
    "market": "CA",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "CA",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "ca-cm-kg/TSXV/RKV",
  "coverage": {
   "count": 0,
   "houses": [],
   "pages_checked": [],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": null,
   "state": "none_found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 1427,
     "median_cadence_gap_days": 19,
     "median_filings": 9,
     "median_latency_days": 17,
     "name": "TSXV"
    },
    "sector": {
     "issuers": 200,
     "median_cadence_gap_days": 17.5,
     "median_filings": 7,
     "median_latency_days": 14,
     "name": "Life Sciences"
    }
   },
   "by_type": {
    "exchange_bulletin": 4,
    "financial_statement": 3,
    "newswire_release": 21
   },
   "cadence_median_gap_days": 12,
   "filing_days": 24,
   "filings": 28,
   "latency_days": 1,
   "latest": [
    {
     "category": null,
     "date": "2026-11-05",
     "source": "https://www.globenewswire.com/news-release/2026/11/05/3397013/0/en/rakovina-therapeutics-announces-shares-for-debt-transaction.html",
     "title": "Rakovina Therapeutics Announces Shares for Debt",
     "type": "newswire_release"
    },
    {
     "category": null,
     "date": "2026-11-05",
     "source": "https://www.globenewswire.com/news-release/2026/11/05/3396131/0/en/rakovina-therapeutics-to-present-brain-penetrant-atr-inhibitor-data-at-the-31st-society-for-neuro-oncology-annual-meeting.html",
     "title": "Rakovina Therapeutics to Present Brain-Penetrant ATR",
     "type": "newswire_release"
    },
    {
     "category": null,
     "date": "2026-11-05",
     "source": "https://www.globenewswire.com/de/news-release/2026/11/05/3397013/0/en/rakovina-therapeutics-announces-shares-for-debt-transaction.html",
     "title": "Rakovina Therapeutics Announces Shares for Debt",
     "type": "newswire_release"
    },
    {
     "category": null,
     "date": "2026-10-28",
     "source": "https://www.globenewswire.com/news-release/2026/10/28/3389918/0/en/rakovina-therapeutics-and-celvion-therapeutics-complete-ai-analysis-identifying-priority-cancer-indications-for-brain-penetrant-atr-inhibitor-program.html",
     "title": "Rakovina Therapeutics and Celvion Therapeutics Complete AI",
     "type": "newswire_release"
    },
    {
     "category": null,
     "date": "2026-10-22",
     "source": "https://www.globenewswire.com/news-release/2026/10/22/3386105/0/en/rakovina-therapeutics-and-variational-ai-advance-brain-penetrant-atr-program-toward-development-candidate-selection.html",
     "title": "Rakovina Therapeutics and Variational AI Advance",
     "type": "newswire_release"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.ca-cm-kg.ai/events/TSXV/RKV",
   "window": {
    "from": "2025-11-06",
    "to": "2026-11-06"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "tsx.com company directory (exchange list)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*",
    "state": "sourced",
    "value": "TSXV"
   },
   "isin": {
    "market": "CA",
    "reason": "no ISIN found on issuer pages",
    "state": "not_on_record"
   },
   "jurisdiction": {
    "read_by": "GLEIF LEI record (LEI per the LEI column)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://api.gleif.org/api/v1/lei-records/254900O0YVEUNI9UM016",
    "state": "sourced",
    "value": "British Columbia (CA-BC)"
   },
   "lei": {
    "read_by": "GLEIF name-exact",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://api.gleif.org/api/v1/lei-records/254900O0YVEUNI9UM016",
    "state": "sourced",
    "value": "254900O0YVEUNI9UM016"
   },
   "name": {
    "read_by": "tsx.com company directory (exchange list)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*",
    "state": "sourced",
    "value": "Rakovina Therapeutics Inc."
   },
   "sector": {
    "read_by": "TMX listed-companies workbook (exchange list, monthly; data month named in the source column)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.tsx.com/en/resource/571 (tsx-and-amp-tsxv-listed-companies-2026-08-14-en.xlsx, data as of 31-Jul-2026)",
    "state": "sourced",
    "value": "Life Sciences"
   },
   "security_type": {
    "read_by": "TMX listed-companies workbook (exchange list, monthly; data month named in the source column)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.tsx.com/en/resource/571 (tsx-and-amp-tsxv-listed-companies-2026-08-14-en.xlsx, data as of 31-Jul-2026)",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "CA",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "tsx.com company directory (exchange list)",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*",
    "state": "sourced",
    "value": "RKV"
   },
   "website": {
    "market": "CA",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": [],
   "listing": [],
   "name_change": [],
   "segment_move": []
  },
  "market": "CA",
  "node": "ca-cm-kg",
  "numbers_hash": "sha256:449727a49ac2a9f473a4feb116a33bf4d1af80ecd3a4ce97a59772b508c11922",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [
    "Paragraph (o) of the definition",
    "Paragraph (q) of the definition"
   ],
   "outcomes": {
    "Paragraph (o) of the definition": {
     "determinable": true,
     "signal": "ACM-200"
    },
    "Paragraph (q) of the definition": {
     "determinable": true,
     "signal": "ACM-200"
    }
   },
   "read": {
    "basis": "one live read per instrument class, halt state and client category on this market; this issuer's group",
    "chapter": "https://mcp.ca-cm-kg.ai/book/aio.json",
    "door": "https://mcp.ca-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "rule_version": "acm-68000/ca/kyp-know-your-product-ni-31-103/r1",
   "section": "ca.aio.v11"
  },
  "record": {
   "as_of": "2026-11-06",
   "url": "https://mcp.ca-cm-kg.ai/record/TSXV/RKV",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://iiroc.mediaroom.com/index.php?s=2429&l=100",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:449727a49ac2a9f473a4feb116a33bf4d1af80ecd3a4ce97a59772b508c11922",
 "path": "/ca/TSXV/RKV",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Rakovina Therapeutics Inc., listed on the TSXV under ticker RKV, with LEI 254900O0YVEUNI9UM016. The ISIN is not on the record. Its security type is Corporate, its segment is not on the record, its sector is Life Sciences, and its jurisdiction is British Columbia (CA-BC). The issuer is listed and not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 28 filings in the twelve months to 2026-11-06, across 24 filing days. The filings are 21 newswire releases, 4 exchange bulletins and 3 financial statements. The median gap between filing days is 12 days. The latest filing is a newswire release dated 2026-11-05, 1 day before the record date. The TSXV median cadence gap is 19 days, and the TSXV median latency is 17.0 days. The Life Sciences sector median cadence gap is 17.5 days, and the sector median latency is 14 days. The TSXV median filings count is 9, and the sector median filings count is 7.0.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is Davidson & Company LLP. The auditor's location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting, name change, domicile change or segment move events. The issuer is listed and not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "Under rule version acm-68000/ca/kyp-know-your-product-ni-31-103/r1, chapter as of 2026-11-04, both client categories return signal ACM-200 and the outcome is determinable: Paragraph (o) of the definition and Paragraph (q) of the definition.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "No research houses were found on the issuer's investor-relations pages read. The count is 0.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found. The count is 0.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The vintage of this market is not sealed. The live record began on 2026-09-10. Years 2021 through 2026 are sealed in the store but are not served as of a date, and the as-of door answers not_sealed.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "8 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.tsx.com/json/company-directory/search/tsxv/^*"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://api.gleif.org/api/v1/lei-records/254900O0YVEUNI9UM016"
  },
  {
   "for": "identity.sector",
   "source": "https://www.tsx.com/en/resource/571"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.ca-cm-kg.ai/events/TSXV/RKV"
  },
  {
   "for": "the halt flag",
   "source": "https://iiroc.mediaroom.com/index.php?s=2429&l=100"
  },
  {
   "for": "the auditor",
   "source": "https://www.biospace.com/press-releases/rakovina-therapeutics-announces-q2-2026-financial-results-and-provides-corporate-update"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.ca-cm-kg.ai/book/aio.json"
  },
  {
   "for": "the record",
   "source": "https://mcp.ca-cm-kg.ai/record/TSXV/RKV"
  }
 ],
 "title": "Rakovina Therapeutics Inc. (RKV) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}